Cover Image
Market Research Report

Global Testicular Cancer Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 294980
Published Content info 111 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Testicular Cancer Drugs Market 2019-2023
Published: January 17, 2019 Content info: 111 Pages
Description

About this market

The availability of combination therapies for the treatment of testicular cancer will drive market growth during the forecast period. Combined drug therapy is more effective compared with single-drug therapy. Researchers are focused on the development of new combination therapies because of their effectiveness in treating testicular cancer. Technavio's analysts have predicted that the testicular cancer drugs market will register a CAGR of over 4%by 2023.

Market Overview

Increasing prevalence of testicular cancer

There has been an increase in the prevalence of testicular cancer globally. Estrogenic activity results in hormonal disruption and is responsible for the gradually increasing incidence of testicular cancer. In 2015, in the US, 17.52% of the total population of men were living with testicular cancer.

Alternative treatment options

The market has alternative treatment options for testicular cancer, including radiation therapy and surgery. Surgery is the first-line treatment in most cases and is generally curative. Radiation therapy is a method in which high-energy X-rays are used to destroy cancer cells. These alternative treatment methods may limit the consumption of drugs and pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the testicular cancer drugs market during the 2019-2023, view our report.view our report.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of few countries. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30683

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis
  • PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Non-seminoma - Market size and forecast 2018-2023
  • Seminoma - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Segments of global oncology therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline drugs in late-stage clinical trials
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Non-seminoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Non-seminoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Seminoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Seminoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Baxter - Vendor overview
  • Exhibit 47: Baxter - Business segments
  • Exhibit 48: Baxter - Organizational developments
  • Exhibit 49: Baxter - Geographic focus
  • Exhibit 50: Baxter - Segment focus
  • Exhibit 51: Baxter - Key offerings
  • Exhibit 52: Bristol-Myers Squibb - Vendor overview
  • Exhibit 53: Bristol-Myers Squibb - Business segments
  • Exhibit 54: Bristol-Myers Squibb - Organizational developments
  • Exhibit 55: Bristol-Myers Squibb - Geographic focus
  • Exhibit 56: Bristol-Myers Squibb - Key offerings
  • Exhibit 57: Eli Lilly - Vendor overview
  • Exhibit 58: Eli Lilly - Product segments
  • Exhibit 59: Eli Lilly - Organizational developments
  • Exhibit 60: Eli Lilly - Geographic focus
  • Exhibit 61: Eli Lilly - Segment focus
  • Exhibit 62: Eli Lilly - Key offerings
  • Exhibit 63: Pfizer - Vendor overview
  • Exhibit 64: Pfizer - Business segments
  • Exhibit 65: Pfizer - Organizational developments
  • Exhibit 66: Pfizer - Geographic focus
  • Exhibit 67: Pfizer - Segment focus
  • Exhibit 68: Pfizer - Key offerings
  • Exhibit 69: Teva Pharmaceutical - Vendor overview
  • Exhibit 70: Teva Pharmaceutical - Business segments
  • Exhibit 71: Teva Pharmaceutical - Organizational developments
  • Exhibit 72: Teva Pharmaceutical - Geographic focus
  • Exhibit 73: Teva Pharmaceutical - Segment focus
  • Exhibit 74: Teva Pharmaceutical - Key offerings
  • Exhibit 75: Validation techniques employed for market sizing
  • Exhibit 76: List of abbreviations
Back to Top